These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6126417)

  • 41. [Behavior of blood ammonia, insulin, glucagon, renin and prolactin during propranolol therapy in cirrhosis patients with portal hypertension].
    Mazzone O; Randazzo G; Catalano D; Noè I
    Clin Ter; 1986 Jul; 118(2):109-14. PubMed ID: 3527539
    [No Abstract]   [Full Text] [Related]  

  • 42. Acute variceal bleeding: pharmacological treatment and primary/secondary prophylaxis.
    Dell'Era A; de Franchis R; Iannuzzi F
    Best Pract Res Clin Gastroenterol; 2008; 22(2):279-94. PubMed ID: 18346684
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Vasopressin, somatostatin and digestive hemorrhages in portal hypertension: the end of the tunnel?].
    Calès P
    Gastroenterol Clin Biol; 1994; 18(8-9):739-42. PubMed ID: 7875444
    [No Abstract]   [Full Text] [Related]  

  • 44. [Hemodynamic disorders due to liver cirrhosis].
    Garbuzenko DV
    Klin Med (Mosk); 1996; 74(2):5-7. PubMed ID: 8772089
    [No Abstract]   [Full Text] [Related]  

  • 45. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.
    Villanueva C; Aracil C; Colomo A; Hernández-Gea V; López-Balaguer JM; Alvarez-Urturi C; Torras X; Balanzó J; Guarner C
    Gastroenterology; 2009 Jul; 137(1):119-28. PubMed ID: 19344721
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The low incidence of bacterial infections could be a protective factor against variceal bleeding per se in hemodynamic responders to propranolol.
    Senzolo M; Cholongitas E; Marelli L; Thalheimer U; Patch D; Burroughs AK
    Am J Gastroenterol; 2006 Oct; 101(10):2436-7. PubMed ID: 17032210
    [No Abstract]   [Full Text] [Related]  

  • 47. Betablocker, hepatic functions and confusion.
    Bhalla A
    J Assoc Physicians India; 1999 Feb; 47(2):254-5. PubMed ID: 10999112
    [No Abstract]   [Full Text] [Related]  

  • 48. [Drug therapy and prevention of hemorrhage in esophageal and gastric varices].
    Kitsenko EA; Peresta IuIu
    Klin Med (Mosk); 1995; 73(2):12-6. PubMed ID: 7541875
    [No Abstract]   [Full Text] [Related]  

  • 49. Propranolol in the treatment of portal hypertension: a caution.
    Conn HO
    Hepatology; 1982; 2(5):641-4. PubMed ID: 6981577
    [No Abstract]   [Full Text] [Related]  

  • 50. [Pharmacological treatment of the portal hypertension].
    Castañeda Romero B
    Rev Gastroenterol Mex; 2005 Nov; 70 Suppl 3():64-5. PubMed ID: 17471863
    [No Abstract]   [Full Text] [Related]  

  • 51. Propranolol: its role in the management of portal hypertension. The ACG Committee on FDA related matters.
    Gitlin N
    Am J Gastroenterol; 1983 Feb; 78(2):124-6. PubMed ID: 6823937
    [No Abstract]   [Full Text] [Related]  

  • 52. Discussion on randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis.
    Castaño G; Viudez P; Frider B; Sookoian S
    Gastroenterology; 2002 May; 122(5):1544-5. PubMed ID: 11984541
    [No Abstract]   [Full Text] [Related]  

  • 53. [Portal hypertension: value of combination of nitrate derivatives and beta blockers for better prevention?].
    Oberti F; Calès P
    Gastroenterol Clin Biol; 1995 Mar; 19(3):328-31. PubMed ID: 7781957
    [No Abstract]   [Full Text] [Related]  

  • 54. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension.
    Hernández-Guerra M; García-Pagán JC; Turnes J; Bellot P; Deulofeu R; Abraldes JG; Bosch J
    Hepatology; 2006 Mar; 43(3):485-91. PubMed ID: 16496307
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Dose-dependent acute effect and long-term modification by molsidomine of portal and cardiac hemodynamics in patients with liver cirrhosis].
    Hüppe D; Jäger D; Tromm A; Barmeyer J; May B
    Med Klin (Munich); 1994 Jul; 89 Suppl 2():65-8, 76. PubMed ID: 7968910
    [No Abstract]   [Full Text] [Related]  

  • 56. Pharmacologic control of posthepatectomy portal hypertension.
    Sirinek KR; Thomford NR
    Surg Forum; 1973; 24():391-3. PubMed ID: 4806035
    [No Abstract]   [Full Text] [Related]  

  • 57. [Pharmacologic treatment or endoscopic sclerotherapy as primary intervention for bleeding varices in cirrhotic patients].
    Grønbaek H; Dahlerup JF; Vilstrup H
    Ugeskr Laeger; 2003 Mar; 165(11):1127-30. PubMed ID: 12677989
    [No Abstract]   [Full Text] [Related]  

  • 58. [CYP2D6 gene polymorphic markers role in determining the optimal treatment tactics for portal hypertension in patients with liver cirrhosis].
    Sychev DA; Parusov AI; Loranskaya ID; Denisenko NP; Akmalova KA; Sozaeva ZA; Turkina OL; Zastrozhin MS
    Ter Arkh; 2022 Feb; 94(2):200-208. PubMed ID: 36286743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of vasopressin and somatostatin on hemodynamics and blood gases in patients with liver cirrhosis.
    Naeije R; Hallemans R; Mols P; Mélot C; Reding P
    Crit Care Med; 1982 Sep; 10(9):578-82. PubMed ID: 6125342
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic-hemodynamic interactions in cirrhosis.
    Blei AT
    Semin Liver Dis; 1986 Nov; 6(4):299-308. PubMed ID: 3544223
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.